Mostrando 10 resultados de: 16
Filtros aplicados
Subtipo de publicación
Article(16)
Publisher
The Lancet(3)
New England Journal of Medicine(2)
The Lancet Global Health(2)
American Heart Journal(1)
Cardiovascular Research(1)
Associations of Fish Consumption with Risk of Cardiovascular Disease and Mortality among Individuals with or without Vascular Disease from 58 Countries
ArticleAbstract: Importance: Cohort studies report inconsistent associations between fish consumption, a major sourcePalabras claves:Autores:Alhabib K.F., Avezum A.J., Chifamba J., Dagenais G.R., Dans A.M., Dehghan M., DIaz R., Gerstein H.C., Gulec S., Gupta R., Hu W., Iqbal R., Kaur M., Khatib R., Lanas F.T., Lear S.A., Mente A., Mohammadifard N., Mohan D., Mohan V., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Rosengren A., Swaminathan S., Szuba A., Teo K.K., Vijayakumar K., Wei L., Wentzel-Viljoen E., Wielgosz A., Yeates K.E., Yusoff K., Yusuf R., Yusuf S., Yusufali A.M.Fuentes:googlescopusAssociations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies
ArticleAbstract: Background Several studies reported a U-shaped association between urinary sodium excretion and cardPalabras claves:Autores:Anand S.S., Avezum A.J., Bahonar A., Chifamba J., Dagenais G.R., DIaz R., Iqbal R., Lanas F., Lear S.A., Li W., Lu Y., Mann J.F.E., McQueen M.J., Mente A., Mony P.K., Oguz A., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Rensheng L., Rosengren A., Schutte A.E., Szuba A., Teo K.K., Yi S., Yusoff K., Yusuf R., Yusuf S., Yusufali A.M.Fuentes:googlescopusAntihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
ArticleAbstract: Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) found that antihypPalabras claves:Blood pressure, candesartan, Cardiovascular disease, Lipoprotein, Primary Prevention, statinAutores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Gao P., Hart R.G., Held C., Khunti K., Leiter L.A., Lewis B.S., Lonn E.M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Reid C.M., Sliwa K., Toff W.D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusGlobal variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals
ArticleAbstract: Aims: To compare the prevalence of electrocardiogram (ECG)-documented atrial fibrillation (or fluttePalabras claves:Atrial Fibrillation, CLSA, epidemiologyAutores:Alhabib K.F., Avezum A.J., Bahonar A., Chifamba J., Connolly S.J., Dagenais G.R., Dans A.M., Douma R., Gupta R., Healey J.S., Huisman H., Ibrahim Q., Islam S., Ismail R., Iype T., Joseph P.G., Kazmi K., Kengne A.P., Keskinler M.V., Kumar R., Lanas F.T., Lear S.A., Mohan V., Mony P.K., Orlandini A., PATRICIO LOPEZ -JARAMILLO, Rahman O., Raina P., Rangarajan S., Rosengren A., Teo K.K., Wei L., Yeates K.E., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:googlescopusFixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
ArticleAbstract: Background: In randomised controlled trials, fixed-dose combination treatments (or polypills) have bPalabras claves:Autores:Avezum A.J., Bangdiwala S.I., Bosch J.J., Castellano J.M., Dagenais G.R., Dans A.M., DIaz R., Fuster V., Gamra H., Gao P., Huffman M.D., Joseph P.G., Liu L., Lonn E.M., Malekzadeh R., Pais P., PATRICIO LOPEZ -JARAMILLO, Prabhakaran D., Rodgers A., Roshandel G., Sliwa K., Teo K.K., Xavier D., Yusuf S., Zhu J.Fuentes:googlescopusEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention: An analysis of the HOPE-3 trial
ArticleAbstract: Background-It is not clear whether the effects of lipid-lowering or antihypertensive medications arePalabras claves:Antihypertensive agent, statinAutores:Avezum A.J., Bogaty P.M., Bosch J.J., Dagenais G.R., Dehghan M., Held C., Jansky P., Jung H., Keltai M., Leiter L.A., Lonn E.M., PATRICIO LOPEZ -JARAMILLO, Toff W.D., Yusuf S.Fuentes:googlescopusMortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusMortality and cardiovascular and respiratory morbidity in individuals with impaired FEV <inf>1</inf> (PURE): an international, community-based cohort study
ArticleAbstract: Background: The associations between the extent of forced expiratory volume in 1 s (FEV 1 ) impairmePalabras claves:Autores:Avezum A.J., Bahonar A., Chifamba J., Dagenais G.R., du Plessis J.L., Duong M.L., Gupta R., Igumbor E.U., Iqbal R., Islam S., Karsidag K., Killian K., Kumar R., Kurmi O.P., Lamelas P.M., Lanas F.T., Lear S.A., Leong D.P., Li W., Lu Y., Mohan V., Mony P.K., Nair S., Noorhassim I., O'Byrne P.M., PATRICIO LOPEZ -JARAMILLO, Rahman O., Rangarajan S., Rosengren A., Teo K.K., Wielgosz A., Yan R., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K., Zhi F.Fuentes:googlescopusInequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study
ArticleAbstract: Background: There is little evidence on the use of secondary prevention medicines for cardiovascularPalabras claves:Autores:Alhabib K.F., Avezum A.J., Bai X., Chifamba J., Chow C.K., Corsi D.J., Dagenais G.R., Dans A.M., DIaz R., Erbakan A.N., Iqbal R., Kelishadi R., Khatib R., Lanas F., Lear S.A., Li W., Liu J., Mckee M., Mohan V., Monsef N., Mony P.K., Murphy A., Noorhassim I., O'Donnell O., Palafox B., PATRICIO LOPEZ -JARAMILLO, Perel P., Puoane T., Rangarajan S., Rosengren A., Schutte A.E., Sintaha M., Stuckler D., Teo K.K., Wielgosz A., Yeates K.E., Yin L., Yusoff K., Yusuf S., Zatońska K.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus